Active positive sloped equalizer for x-band SiGe BiCMOS phased array applications

This work presents an active equalizer circuit with positive gain slope at X-Band (8 - 12 GHz). Compared to passive examples, the active equalizer realized better filter and impedance characteristics in frequency of interest with increased functionality for a single amplification stage. It achieved close to 10 dB of peak gain, a + 1.13 dB/GHz gain slope with 2.8 dB NF by utilizing cascode topology. The design reaches a -1.5 dBm input-referred compression point (input-P1dB) while consuming 46 mW of power. To the best of authors’ knowledge, the presented work achieves the best on-chip gain, a gain slope and NF performance in the literature as an equalizer that utilizes SiGe BiCMOS technology

Patterns in use and transplant outcomes among adult recipients of kidneys from deceased donors with COVID-19

IMPORTANCE: While the COVID-19 pandemic enters a new phase and the proportion of individuals with a previous COVID-19 diagnosis increases, the national patterns in kidney use and medium-term kidney transplant (KT) outcomes among patients receiving kidneys from active or resolved COVID-19-positive donors remain unknown. OBJECTIVE: To evaluate the patterns in kidney use and KT outcomes among adult recipients of kidneys from deceased donors with active or resolved COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was conducted using national US transplant registry data from 35 851 deceased donors (71 334 kidneys) and 45 912 adult patients who received KTs from March 1, 2020, to March 30, 2023. EXPOSURE: The exposure was donor SARS-CoV-2 nucleic acid amplification test (NAT) results, with positive NAT results within 7 days before procurement defined as active COVID-19 and positive NAT results 1 week (\u3e7 days) before procurement defined as resolved COVID-19. MAIN OUTCOMES AND MEASURES: Primary outcomes were kidney nonuse, all-cause kidney graft failure, and all-cause patient death. Secondary outcomes were acute rejection (ie, rejection in the first 6 months after KT), transplant hospitalization length of stay (LOS), and delayed graft function (DGF). Multivariable logistic regression analyses were performed for kidney nonuse, rejection, and DGF; multivariable linear regression analyses were performed for LOS; and multivariable Cox regression analyses were performed for graft failure and all-cause death. All models were adjusted for inverse probability treatment weighting. RESULTS: Among 35 851 deceased donors, the mean (SD) age was 42.5 (15.3) years; 22 319 (62.3%) were men and 23 992 (66.9%) were White. Among 45 912 recipients, the mean (SD) age was 54.3 (13.2) years; 27 952 (60.9%) were men and 15 349 (33.4%) were Black. The likelihood of nonuse of kidneys from active or resolved COVID-19-positive donors decreased over time. Overall, kidneys from active COVID-19-positive donors (adjusted odds ratio [AOR], 1.55; 95% CI, 1.38-1.76) and kidneys from resolved COVID-19-positive donors (AOR, 1.31; 95% CI, 1.16-1.48) had a higher likelihood of nonuse compared with kidneys from COVID-19-negative donors. From 2020 to 2022, kidneys from active COVID-19-positive donors (2020: AOR, 11.26 [95% CI, 2.29-55.38]; 2021: AOR, 2.09 [95% CI, 1.58-2.79]; 2022: AOR, 1.47 [95% CI, 1.28-1.70]) had a higher likelihood of nonuse compared with kidneys from donors without COVID-19. Kidneys from resolved COVID-19-positive donors had a higher likelihood of nonuse in 2020 (AOR, 3.87; 95% CI, 1.26-11.90) and 2021 (AOR, 1.94; 95% CI, 1.54-2.45) but not in 2022 (AOR, 1.09; 95% CI, 0.94-1.28). In 2023, kidneys from both active COVID-19-positive donors (AOR, 1.07; 95% CI, 0.75-1.63) and resolved COVID-19-positive donors (AOR, 1.18; 95% CI, 0.80-1.73) were not associated with higher odds of nonuse. No higher risk of graft failure or death was found in patients receiving kidneys from active COVID-19-positive donors (graft failure: adjusted hazard ratio [AHR], 1.03 [95% CI, 0.78-1.37]; patient death: AHR, 1.17 [95% CI, 0.84-1.66]) or resolved COVID-19-positive donors (graft failure: AHR, 1.10 [95% CI, 0.88-1.39]; patient death: AHR, 0.95 [95% CI, 0.70-1.28]). Donor COVID-19 positivity was not associated with longer LOS, higher risk of acute rejection, or higher risk of DGF. CONCLUSIONS AND RELEVANCE: In this cohort study, the likelihood of nonuse of kidneys from COVID-19-positive donors decreased over time, and donor COVID-19 positivity was not associated with worse KT outcomes within 2 years after transplant. These findings suggest that the use of kidneys from donors with active or resolved COVID-19 is safe in the medium term; further research is needed to assess longer-term transplant outcomes

An x-band 6-bit active phase shifter

This paper presents a 6-bit active phase shifter using a new vector-sum method for X-band (8-12 GHz) phased arrays in 0.13 mu m SiGe BiCMOS process. An RC filter is used to generate two orthogonal vectors which are then fed into four VGAs, two using the common-base and two using the common-emitter topology. This generates 4 vectors of 0 degrees, 90 degrees, 180 degrees and 270 degrees which are scaled and added by varying the gains of the VGAs to generate any phase between 0-360 degrees. The gains of the VGAs are adjusted with analog voltage control using the current-steering method. The outputs of the VGAs are connected together with a common load in order to add the vectors in current-domain. The phase shifter achieves < 5.6 degrees RMS phase error over 8-12 GHz and < 3.1 degrees RMS phase error over 9-11 GHz. The phase shifter has a power consumption of 16.6 mW from a 2V supply. The chip size is 850 mu m x 532 mu m including the probing pads. These performance parameters are comparable with the state of the art of the technology in literature

A wideband low noise SiGe medium power amplifier for x-band phased array applications

This paper presents a Medium Power Amplifier (MPA) for X-Band Phased Array RADAR applications in 0.25 mu m SiGe technology. The MPA is designed such that it achieves high output power and low noise simultaneously that enables its use in Transmitter/ Receiver (T/R) core module as a Low Noise Amplifier (LNA). The MPA achieves 23.6dB peak gain and 17.3dB maximum output power at 10GHz with a power consumption of 190mW. Its input and output is matched in a 7 GHz of bandwidth, while its mean Noise Figure (NF) is about 3dB throughout the defined bandwidth. According to authors' knowledge, this work presents state-of-the-art wideband MPA performances in literature, with 7GHz of operational bandwidth and 17.3dBm output power

A SiGe BiCMOS bypass low-noise amplifier for x-band phased array RADARs

This paper presents a bypass low noise amplifier (LNA) for X-band phased array applications in 0.25μm SiGe BiCMOS technology. The trade-off between gain and bypass modes is considered to achieve high gain as well as low noise figure for gain mode while maintaining reasonable insertion loss with high power handling capability in bypass mode. In gain mode, the LNA achieves a measured gain of 17-14.2 dB and a noise figure of 1.75-1.95 dB over the 8-12 GHz band while consuming 27.4mW of DC-power. The measured input-referred I-dB compression point (IP 1dB ) is -3.9 dBm at 10 GHz. When operating in bypass mode, the measured insertion loss is 6.5-5.95 dB over the entire X-band with the measured IP 1dB of 15.1 dBm at 10 GHz, and it dissipates only 1μW power. Thanks to the bypassing technique, an increase of about 19 dB is achieved for IP 1dB in bypass mode compare to the gain mode. The measured return losses are better than 10 dB for both operating modes over whole X-band. The effective chip area excluding the pads is 0.3 mm 2

A wideband high isolation CMOS T/R switch for x-band phased array radar systems

This paper presents an SPDT switch which is designed to operate at 8-12 GHz frequency range (X-Band), as a sub module of the front end circuit of a phased array radar. The switch distinguishes itself from its counterparts with its larger frequency range and higher isolation that is uniformly distributed over its bandwidth. It is fabricated using 0.25 mu m SiGe BiCMOS technology of IHP Microelectronics (Germany). As a new technique, shunt inductors are placed next to shunt transistors in order to improve trade-off between insertion loss and isolation. It has isolation higher than 30 dB in entire band, input referred 1dB compression point is 27.6 dBm, insertion loss is between 2.7-4.1 dB, input and output referred return losses are better than 11 dB in the frequency range of 8-12 Gliz

Operational challenges in the COVID‐19 era: Asymptomatic infections and vaccination timing

The coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges for solid organ transplant programs. While transplant activity has largely recovered, appropriate management of deceased donor candidates who are asymptomatic but have positive nucleic acid test (NAT) for COVID-19 is unclear as this may reflect active infection or prolonged viral shedding. Furthermore, candidates who are unvaccinated or partially vaccinated continue to receive donor offers. In the absence of prospective data, transplant professionals at U.S. adult kidney transplant centers were surveyed to determine community practice (N: 92 centers, capturing 40.8% of centers and 56.6% of transplants performed). The majority (96.8%) of responding centers declined organs for asymptomatic NAT+ patients without documented prior infection. However, 31.6% of centers proceeded with kidney transplant in NAT+ patients who were at least 30 days from initial diagnosis with negative chest imaging. Less than 7% of programs reported inactivating patients who were unvaccinated or partially vaccinated. In conclusion, despite national recommendations to wait for negative testing, many centers are proceeding with transplant in patients with positive tests due to presumed viral shedding. Furthermore, very few centers are requiring COVID-19 vaccination prior to transplantation despite early evidence suggesting reduced immunogenicity in transplant patients on immunosuppression

The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis

Membranous Nephropathy (MN) is a rare autoimmune cause of kidney failure. Here we report a genome-wide association study (GWAS) for primary MN in 3,782 cases and 9,038 controls of East Asian and European ancestries. We discover two previously unreported loci, NFKB1 (rs230540, OR = 1.25, P = 3.4 × 10−12) and IRF4 (rs9405192, OR = 1.29, P = 1.4 × 10−14), fine-map the PLA2R1 locus (rs17831251, OR = 2.25, P = 4.7 × 10−103) and report ancestry-specific effects of three classical HLA alleles: DRB1*1501 in East Asians (OR = 3.81, P = 2.0 × 10−49), DQA1*0501 in Europeans (OR = 2.88, P = 5.7 × 10−93), and DRB1*0301 in both ethnicities (OR = 3.50, P = 9.2 × 10−23 and OR = 3.39, P = 5.2 × 10−82, respectively). GWAS loci explain 32% of disease risk in East Asians and 25% in Europeans, and correctly re-classify 20–37% of the cases in validation cohorts that are antibody-negative by the serum anti-PLA2R ELISA diagnostic test. Our findings highlight an unusual genetic architecture of MN, with four loci and their interactions accounting for nearly one-third of the disease risk

The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis

Membranous Nephropathy (MN) is a rare autoimmune cause of kidney failure. Here we report a genome-wide association study (GWAS) for primary MN in 3,782 cases and 9,038 controls of East Asian and European ancestries. We discover two previously unreported loci, NFKB1 (rs230540, OR = 1.25, P = 3.4 × 10-12) and IRF4 (rs9405192, OR = 1.29, P = 1.4 × 10-14), fine-map the PLA2R1 locus (rs17831251, OR = 2.25, P = 4.7 × 10-103) and report ancestry-specific effects of three classical HLA alleles: DRB1*1501 in East Asians (OR = 3.81, P = 2.0 × 10-49), DQA1*0501 in Europeans (OR = 2.88, P = 5.7 × 10-93), and DRB1*0301 in both ethnicities (OR = 3.50, P = 9.2 × 10-23 and OR = 3.39, P = 5.2 × 10-82, respectively). GWAS loci explain 32% of disease risk in East Asians and 25% in Europeans, and correctly re-classify 20-37% of the cases in validation cohorts that are antibody-negative by the serum anti-PLA2R ELISA diagnostic test. Our findings highlight an unusual genetic architecture of MN, with four loci and their interactions accounting for nearly one-third of the disease risk